Table 1.
Clinical characteristics of the three main studies compared in this report, showing similarities and differences observed between the two axSpA subtypes
| Local cohort14 | National cohort15 | Worldwide study14 | ||||
|---|---|---|---|---|---|---|
| nr-axSpA (n=44) | AS (n=56) | nr-axSpA (n=226) | AS (n=236) | nr-axSpA (n=157) | AS (n=178) | |
| Mean age | 39.1±9.8 | 41.2±10.9 | 36.1±10.6 | 35.6±10.2 | 37.4±11.8 | 41.5±11.6 |
| HLA-B27 pos. (%) | 86.4 | 89.1 | 74.4 | 82.2 | 74.8 | 81.5 |
| Male (%) | 31.8 | 76 | 42.9 | 64.0 | 48.3 | 72.5 |
| Peripheral arthritis (%) | 18.2 | 17.9 | 18.2 | 14.4 | 54.4 | 53.9 |
| Enthesitis (%) | 2.3 | 1.8 | 24.8 | 20.8 | – | – |
| Uveitis (%) | 6.8 | 5.4 | 2.2 | 1.7 | – | – |
| Psoriasis (%) | 9.1 | 10.7 | 5.3 | 8.1 | – | – |
| IBD (%) | 6.8 | 5.4 | 0.9 | 1.7 | – | – |
| Mean BASDAI | 3.6±1.7 | 4.2±2.2 | 3.9±2.0 | 4.0±2.1 | 6.5±1.5 | 6.4±1.6 |
| Mean BASFI | 2.4±2.1 | 3.2±2.4 | 2.5±2.1 | 3.1±2.5 | 4.9±2.3 | 5.7±2.2 |
| Mean BASMI | – | – | 1.1±1.3 | 2.0±1.8 | 3.2±1.5 | 4.4±1.7 |
| Mean CRP (mg/L) | 5.7±6.5 | 11.6±12.6 | 10.9±18.7 | 14.8±16.0 | 11.9 (0.1,156.2) | 14.3 (0.1, 174.8) |
| Patient's global | 4.0±2.7 | 4.6±2.7 | 4.9±2.5 | 5.0±2.5 | – | – |
| NRS pain | 4.0±2.1 | 4.72.7 | 4.8±2.5 | 5.0±2.5 | – | – |
| Inflamed spinal lesions/patient (%) | 9.1 | 46.4 | – | – | – | – |
AS, ankylosing spondylitis; BASDAI, Bath AS disease activity index; BASFAI, Bath AS function index; BASMI, Bath AS mobility index; CRP, C reactive protein; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; nr-axSpA, non-radiographic axial spondyloarthritides; NRS, numeric rating scale.